Suppr超能文献

合成并评估了对 SARS-CoV-2 具有体外抑制活性的羟氯喹对映异构体。

Synthesis and evaluation of enantiomers of hydroxychloroquine against SARS-CoV-2 in vitro.

机构信息

State Key Laboratory of Natural Medicines, and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 210009, China.

The State Key Laboratory of Anti-Infective Drug Development, Sunshine Lake Pharma Co. Ltd, Dongguan 523871, China.

出版信息

Bioorg Med Chem. 2022 Jan 1;53:116523. doi: 10.1016/j.bmc.2021.116523. Epub 2021 Nov 22.

Abstract

Since the end of 2019, the outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has evolved into a global pandemic. There is an urgent need for effective and low-toxic antiviral drugs to remedy Remdesivir's limitation. Hydroxychloroquine, a broad spectrum anti-viral drug, showed inhibitory activity against SARS-CoV-2 in some studies. Thus, we adopted a drug repurposing strategy, and further investigated hydroxychloroquine. We obtained different configurations of hydroxychloroquine side chains by using chiral resolution technique, and successfully furnished R-/S-hydroxychloroquine sulfate through chemical synthesis. The R configuration of hydroxychloroquine was found to exhibit higher antiviral activity (EC50 = 3.05 μM) and lower toxicity in vivo. Therefore, R-HCQ is a promising lead compound against SARS-CoV-2. Our research provides new strategy for the subsequent research on small molecule inhibitors against SARS-CoV-2.

摘要

自 2019 年底以来,严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)的爆发已演变成全球大流行。迫切需要有效且低毒的抗病毒药物来弥补瑞德西韦的局限性。羟氯喹是一种广谱抗病毒药物,一些研究表明其对 SARS-CoV-2 具有抑制活性。因此,我们采用了药物再利用策略,并进一步研究了羟氯喹。我们通过手性拆分技术获得了羟氯喹侧链的不同构型,并通过化学合成成功合成了 R-/S-羟氯喹硫酸盐。研究发现,羟氯喹的 R 构型表现出更高的抗病毒活性(EC50=3.05 μM)和更低的体内毒性。因此,R-HCQ 是一种有前途的抗 SARS-CoV-2 先导化合物。我们的研究为随后针对 SARS-CoV-2 的小分子抑制剂的研究提供了新的策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0230/8606320/b2528eb1f285/ga1_lrg.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验